Ознакомительная версия. Доступно 13 страниц из 61
6. [Guideline] Chalasani N.P. Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J. et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014 Jul. 109 (7): 950–966; quiz 967.
7. Stine J.G., Lewis J.H. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016. 10 (4): 517–536.
Часть 2. Глава 5
1. Aggarwal R., Goel A. Hepatitis A: epidemiology in resource-poor countries. Curr Opin Infect Dis. 2015 Oct. 28(5): 488–496.
2. Worns M.A., Teufel A., Kanzler S. et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol. 2008 Jan. 103 (1): 138–146.
3. Kanda T., Nakamoto S., Wu S. et al. Direct-acting antivirals and host-targeting agents against the hepatitis A virus. J Clin Transl Hepatol. 2015 Sep 28. 3(3): 205–210.
4. Linder K.A., Malani P.N. Hepatitis A. JAMA. 2017 Dec 19. 318 (23): 2393.
5. Kamar N., Bendall R., Legrand-Abravanel F. et al. Hepatitis E. Lancet. 2012 Jun 30. 379 (9835): 2477–2488.
6. Hoofnagle J.H., Nelson K.E., Purcell R.H. Hepatitis E. N Engl J Med. 2012 Sep 27. 367 (13): 1237–1244.
7. Mushahwar I.K. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention. J Med Virol. 2008 Apr. 80 (4): 646–658.
8. Nelson K.E., Heaney C.D., Labrique A.B., Kmush B.L., Krain L.J. Hepatitis E: prevention and treatment. Curr Opin Infect Dis. 2016 Oct. 29 (5): 478–485.
9. Wedemeyer H., Pischke S., Manns M.P. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology. 2012 May. 142 (6): 1388–1397.e1.
10. Debing Y., Moradpour D., Neyts J., Gouttenoire J. Update on hepatitis E virology: Implications for clinical practice. J Hepatol. 2016 Jul. 65(1): 200–212.
11. [Guideline] European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol. 2018 Jun. 68 (6): 1256–1271.
12. [Guideline] American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Updated: May 24, 2018.
13. [Guideline] World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva, Switzerland: World Health Organization. July 2018.
14. Sterling R.K., Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006 Feb. 8 (1): 53–59.
15. Kamili S., Drobeniuc J., Araujo A.C., Hayden T.M. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012 Jul. 55 suppl 1: S43–438.
16. Yang D.H, Ho L.J, Lai J.H. Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J Gastroenterol. 2014 Mar 21. 20 (11): 2962–2970.
17. Omar H., E.l. Akel W., Elbaz T. et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018 Feb. 47 (3): 421–431.
18. Shahid I., AlMalki W.H., Hassan S., Hafeez M.H. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol. 2018 Mar. 44 (2): 143–160.
19. Te H.S., Jensen D.M. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010 Feb. 14 (1): 1–21, vii.
20. Kuo A., Gish R. Chronic hepatitis B infection. Clin Liver Dis. 2012 May. 16 (2): 347–369.
21. Lau J.Y., Wright T.L. Molecular virology and pathogenesis of hepatitis B. Lancet. 1993 Nov 27. 342 (8883): 1335–1340.
22. [Guideline] Terrault N.A., Lok A.S.F., McMahon B.J. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr. 67 (4): 1560–1599.
23. [Guideline] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug. 67 (2): 370–398.
24. Schiff E.R., Lee S.S., Chao Y.C. et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011 Mar. 9 (3): 274–276.
25. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology. 2009 May. 49(5 suppl):S156-65.
26. Bean P. Latest discoveries on the infection and coinfection with hepatitis D virus. Am Clin Lab. 2002 Jun. 21 (5): 25–27.
27. Xiridou M., Borkent-Raven B., Hulshof J., Wallinga J. How hepatitis D virus can hinder the control of hepatitis B virus. PLoS One. 2009. 4 (4): e5247.
28. Abbas Z., Afzal R. Life cycle and pathogenesis of hepatitis D virus: a review. World J Hepatol. 2013 Dec 27. 5 (12): 666–675.
29. Bahcecioglu I.H., Sahin A. Treatment of delta hepatitis: today and in the future – a review. Infect Dis (Lond). 2017 Apr. 49 (4): 241–250.
30. Alfaiate D., Deny P., Durantel D. Hepatitis delta virus: from biological and medical aspects to current and investigational therapeutic options. Antiviral Res. 2015 Oct. 122: 112–129.
31. Goyal A., Murray J.M. Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication. Theor Popul Biol. 2016 Dec. 112: 60–69.
Часть 2. Глава 6
1. Strassburg C.P., Manns M.P. Treatment of autoimmune hepatitis. Semin Liver Dis. 2009 Aug. 29 (3): 273–285.
2. Longhi M.S, Ma. Y., Mieli-Vergani G., Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun. 2010 Feb. 34 (1): 7–14.
3. Vento S., Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis? Autoimmun Rev. 2004 Jan. 3 (1): 61–69.
4. Umemura T., Ota M. Genetic factors affect the etiology, clinical characteristics and outcome of autoimmune hepatitis. Clin J Gastroenterol. 2015 Dec. 8 (6): 360–366.
5. Czaja A.J. Diagnosis and management of autoimmune hepatitis. Clin Liver Dis. 2015 Feb. 19 (1): 57–79.
6. [Guideline] Gleeson D., Heneghan M.A. British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011 Dec. 60 (12): 1611–1629.
7. Floreani A., Rizzotto E.R., Ferrara F. et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005 Jul. 100 (7): 1516–1522.
Ознакомительная версия. Доступно 13 страниц из 61
